Trivalent NDV-HXP-S Vaccine Protects Against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice

Overview

Journal bioRxiv

Date 2022 Mar 30

PMID 35350201

Authors

Irene Gonzalez-Dominguez

Jose Luis Martinez

Stefan Slamanig

Nicholas Lemus

Yonghong Liu

Tsoi Ying Lai

Juan Manuel Carreno

Gagandeep Singh A

Gagandeep Singh B

Michael Schotsaert

Ignacio Mena

Stephen McCroskery

Lynda Coughlan

Florian Krammer

Adolfo Garcia-Sastre

Peter Palese

Weina Sun

Affiliations

Soon will be listed here.

Abstract

Equitable access to vaccines is necessary to limit the global impact of the coronavirus disease 2019 (COVID-19) pandemic and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. In previous studies, we described the development of a low-cost vaccine based on a Newcastle Disease virus (NDV) expressing the prefusion stabilized spike protein from SARS-CoV-2, named NDV-HXP-S. Here, we present the development of next-generation NDV-HXP-S variant vaccines, which express the stabilized spike protein of the Beta, Gamma and Delta variants of concerns (VOC). Combinations of variant vaccines in bivalent, trivalent and tetravalent formulations were tested for immunogenicity and protection in mice. We show that the trivalent preparation, composed of the ancestral Wuhan, Beta and Delta vaccines, substantially increases the levels of protection and of cross-neutralizing antibodies against mismatched, phylogenetically distant variants, including the currently circulating Omicron variant.

References

Garcia-Beltran W, Lam E, St Denis K, Nitido A, Garcia Z, Hauser B . Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184(9):2372-2383.e9. PMC: 7953441. DOI: 10.1016/j.cell.2021.03.013. View

Wang X, Zhao X, Song J, Wu J, Zhu Y, Li M . Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerg Microbes Infect. 2022; 11(1):477-481. PMC: 8820826. DOI: 10.1080/22221751.2022.2030200. View

Carreno J, Alshammary H, Tcheou J, Singh G, Raskin A, Kawabata H . Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. 2022; 602(7898):682-688. DOI: 10.1038/s41586-022-04399-5. View

Mahase E . Omicron sub-lineage BA.2 may have "substantial growth advantage," UKHSA reports. BMJ. 2022; 376:o263. DOI: 10.1136/bmj.o263. View

Ter Meulen J, van den Brink E, Poon L, Marissen W, Leung C, Cox F . Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006; 3(7):e237. PMC: 1483912. DOI: 10.1371/journal.pmed.0030237. View

Hadfield J, Megill C, Bell S, Huddleston J, Potter B, Callender C . Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018; 34(23):4121-4123. PMC: 6247931. DOI: 10.1093/bioinformatics/bty407. View

Ayllon J, Garcia-Sastre A, Martinez-Sobrido L . Rescue of recombinant Newcastle disease virus from cDNA. J Vis Exp. 2013; (80). PMC: 3939320. DOI: 10.3791/50830. View

Dang A, Vu T, Hai Vu H, Ta V, Van Pham A, Dang M . Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Vaccine. 2022; 40(26):3621-3632. PMC: 9106407. DOI: 10.1016/j.vaccine.2022.04.078. View

Sparrow E, Wood J, Chadwick C, Newall A, Torvaldsen S, Moen A . Global production capacity of seasonal and pandemic influenza vaccines in 2019. Vaccine. 2020; 39(3):512-520. PMC: 7814984. DOI: 10.1016/j.vaccine.2020.12.018. View

10.

Tcheou J, Raskin A, Singh G, Kawabata H, Bielak D, Sun W . Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. Front Immunol. 2021; 12:791764. PMC: 8637447. DOI: 10.3389/fimmu.2021.791764. View

11.

Sun W, Leist S, McCroskery S, Liu Y, Slamanig S, Oliva J . Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine. 2020; 62:103132. PMC: 7679520. DOI: 10.1016/j.ebiom.2020.103132. View

12.

Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul S, Sivakorn C . Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. EClinicalMedicine. 2022; 45:101323. PMC: 8903824. DOI: 10.1016/j.eclinm.2022.101323. View

13.

Rathnasinghe R, Strohmeier S, Amanat F, Gillespie V, Krammer F, Garcia-Sastre A . Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect. 2020; 9(1):2433-2445. PMC: 7655046. DOI: 10.1080/22221751.2020.1838955. View

14.

Ikegame S, Hashiguchi T, Hung C, Dobrindt K, Brennand K, Takeda M . Fitness selection of hyperfusogenic measles virus F proteins associated with neuropathogenic phenotypes. Proc Natl Acad Sci U S A. 2021; 118(18). PMC: 8106313. DOI: 10.1073/pnas.2026027118. View

15.

Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M . A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020; 26(7):1033-1036. PMC: 8183627. DOI: 10.1038/s41591-020-0913-5. View

16.

Sagulenko P, Puller V, Neher R . TreeTime: Maximum-likelihood phylodynamic analysis. Virus Evol. 2018; 4(1):vex042. PMC: 5758920. DOI: 10.1093/ve/vex042. View

17.

Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar G . SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol. 2020; 57(1):e100. PMC: 7235504. DOI: 10.1002/cpmc.100. View

18.

Sun W, McCroskery S, Liu W, Leist S, Liu Y, Albrecht R . A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines (Basel). 2020; 8(4). PMC: 7766959. DOI: 10.3390/vaccines8040771. View

19.

Sun W, Liu Y, Amanat F, Gonzalez-Dominguez I, McCroskery S, Slamanig S . A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nat Commun. 2021; 12(1):6197. PMC: 8551302. DOI: 10.1038/s41467-021-26499-y. View

20.

Hsieh C, Goldsmith J, Schaub J, DiVenere A, Kuo H, Javanmardi K . Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020; 369(6510):1501-1505. PMC: 7402631. DOI: 10.1126/science.abd0826. View